Literature DB >> 22896752

The genealogy of SEREX.

Michael Pfreundschuh1.   

Abstract

Keywords:  Lloyd Old; SEREX; autologous typing; serological expression cloning; tumor antigens

Mesh：

Substances：

Year:  2012        PMID： 22896752      PMCID： PMC3380345     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN： 1424-9634


× No keyword cloud information.
  11 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin.

Authors:  M Pfreundschuh; E Mommertz; M Meissner; A C Feller; R Hassa; G R Krueger; V Diehl
Journal:  Anticancer Res       Date:  1988 Mar-Apr       Impact factor: 2.480

3.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

4.  Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines.

Authors:  P Carde; L Da Costa; L Manil; M Pfreundschuh; J D Lumbroso; J C Saccavini; B Caillou; M Ricard; F Boudet; M Hayat
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

5.  AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Authors:  T E Carey; K O Lloyd; T Takahashi; L R Travassos; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.

Authors:  C Renner; W Jung; U Sahin; R Denfeld; C Pohl; L Trümper; F Hartmann; V Diehl; R van Lier; M Pfreundschuh
Journal:  Science       Date:  1994-05-06       Impact factor: 47.728

Review 7.  Treatment of Hodgkin's disease with bispecific antibodies.

Authors:  F Hartmann; C Renner; W Jung; U Sahin; M Pfreundschuh
Journal:  Ann Oncol       Date:  1996       Impact factor: 32.976

8.  Human neoplasms elicit multiple specific immune responses in the autologous host.

Authors:  U Sahin; O Türeci; H Schmitt; B Cochlovius; T Johannes; R Schmits; F Stenner; G Luo; I Schobert; M Pfreundschuh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

9.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

10.  Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.

Authors:  H Shiku; T Takahashi; H F Oettgen
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307
View more
  3 in total

Review 1.  A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.

Authors:  Alexander C Huang; Roberta Zappasodi
Journal:  Nat Immunol       Date:  2022-03-03       Impact factor: 31.250

Review 2.  B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.

Authors:  Giulia Chiaruttini; Silvia Mele; James Opzoomer; Silvia Crescioli; Kristina M Ilieva; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

3.  Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.

Authors:  Tyler W Hulett; Shawn M Jensen; Phillip A Wilmarth; Ashok P Reddy; Carmen Ballesteros-Merino; Michael E Afentoulis; Christopher Dubay; Larry L David; Bernard A Fox
Journal:  J Immunother Cancer       Date:  2018-04-05       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.